Caricamento...

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

Patients with pancreatic ductal adenocarcinoma (PDA) have a poor prognosis—in spite of new treatments, approximately 7% survive for 5 years. Although there have been advances in systemic, primarily cytotoxic, therapies, it has been a challenge to treat patients with PDA using targeted therapies. Seq...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gastroenterology
Autori principali: Knudsen, Erik S., O’Reilly, Eileen M., Brody, Jonathan R., Witkiewicz, Agnieszka K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5010785/
https://ncbi.nlm.nih.gov/pubmed/26385075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2015.08.056
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !